Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7...
Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients ...
Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational...
Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational...
Harbour BioMed (HBM) (HKEX: 02142.HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to...
Harbour BioMed (HBM)(HKEX:02142), and Utrecht University (UU) today announced that they licensed to AbbVie their fully human, SARS-CoV-2 neutralizing ...
Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company today announced that the company will present the phase II clinical trial...
Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today the dosing of the first patient in two separate Phase II...
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND)...
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company today announced a strategic partnership agreement with Hualan...
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered novel anti-human CCR8 mAbs...
Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented its newly developed HBICETM (HCAb...
Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company today announced that it has entered into a strategic collaboration with Vir...
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered Bispecific Antibody - BCMA x CD3 ...
Harbour BioMed (HBM), and its partners Utrecht University and Erasmus Medical Center, today announced a new research collaboration with...
Harbour BioMed (HBM), a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd. ("Viva Biotech"), a world-leading...
Harbour BioMed (HBM), a global clinical stage biopharmaceutical company, today announced that the Company presented preclinical data from a fully...
Harbour BioMed (HBM) announced today the appointment of Dr. Jon Wigginton M.D., to the company's scientific advisory board (SAB). Dr. Wigginton is a...
Harbour BioMed (HBM) today announced first patient dosing in a Phase 1b/2a study of its anti-FcRn antibody, batoclimab (HBM9161), for the treatment...
Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) today announced they are entering into a strategic alliance to discover,...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.